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Micropeptides represent an emerging class of eukaryotic regulators that are easily missed in conventional
genome annotation. Anderson et al. (2015) describe how a new tissue-specific micropeptide, myoregulin
(MLN), interacts with the skeletal muscle calcium handling machinery to moderate contractile activity, repre-
senting a promising drug target for improving muscle performance.From professional athletes at one
extreme to patients with degenerative
muscle diseases at the other, the effective
function of our musculature is of critical
importance. It is a growing issue in an
increasingly elderly population, where
the age-related decline in muscle function
impedes quality of life and is emerging as
a confounder of many age-related medi-
cal conditions. It is hardly surprising then
that boosting the functional capacity of
skeletal muscle is a current area of intense
study. Of the many factors affecting mus-
cle performance, calcium handling plays
a central role in regulating contractile
function. In striated muscle cells, the
sarco/endoplasmic reticulum Ca-ATPase
(SERCA) is a membrane protein respon-
sible for the active removal of cytosolic
calcium away from contractile proteins,
sequestering it in the lumen of the sarco-
plasmic reticulum (SR) to allow muscle
relaxation (reviewed in Bassel-Duby and
Olson, 2006). The SERCA protein family
includes SERCA1, expressed in all skel-
etal muscle fibers, whereas SERCA2
predominates in heart and slow skeletal
muscle fibers. The rate at which SERCA
pumps calcium ions across the SR mem-
brane has a direct impact on muscle
performance and is controlled by the
association with regulatory proteins phos-
pholamban (PLN) and sarcolipin (SLN),
both of which reduce the rate of calcium
movement in heart and slow skeletal mus-
cle fibers, modulating SERCA pump func-
tion. This has left fast muscle fibers, the
most prevalent and powerful components
of mammalian skeletal muscle, without
a corresponding calcium handling con-
trol—until now.While hunting for new skeletal muscle
genes in an unbiased bioinformatics
screen, Olson and colleagues (Anderson
et al., 2015) stumbled upon a missing
member of the SERCA regulatory protein
family, which they call myoregulin (MLN).
This 46-aa micropeptide had been
missed for years, hidden in an uncharac-
terized vertebrate transcript annotated
as a long noncoding RNA (lncRNA). The
tiny 138-bp open reading frame (ORF)
embedded in the third exon of the MLN
transcript is heavily conserved between
mouse and human and is expressed
exclusively in skeletal muscle during
embryogenesis and into adulthood. Like
its related protein family members PLN
and SLN, the MLN micropeptide com-
prises a single-pass transmembrane a
helix that interacts specifically with
SERCA. Elegant analyses in cultured skel-
etal muscle cells showed that MLN regu-
lates SR calcium levels by inhibiting
SERCA1 pump activity (Figure 1). The
MLN gene is controlled in both fast and
slow fibers by a core muscle transcription
circuit, with functional binding sites in its
promoter for MyoD and MEF2, both of
which regulate skeletal myogenesis.
When the group knocked out MLN gene
function using TALEN technology in
mice, the results were subtle but striking:
the healthy animals were better per-
formers in treadmill tests, running 55%
longer distances than their wild-type lit-
termates. Although no structural changes
in muscle fiber size or composition were
detected, skeletal myoblasts cultured
from the MLN KO mice showed signifi-
cantly increased SR calcium levels.
Neither the expression of SERCA1 norCell Metabolismthe ryanodine receptor, which pumps
out calcium from the SR, was affected in
MLN KO cells, nailing the function of
MLN as the dominant regulator of
SERCA1 activity in adult skeletal muscle
and solving a longstanding mystery.
The discovery of a micropeptide
embedded in a sea of untranslated
lncRNA sequences is not novel: indeed,
in hindsight the MLN structure is not sur-
prising, given that both its cousins, PLN
and SLN, also exist as micropeptides
within larger transcripts (Fujii et al., 1987;
Odermatt et al., 1997). So why did such
an important regulator of muscle contrac-
tility go missing for so long, and what
other hidden treasures lie undetected in
the hundreds of lncRNA sequences en-
coded in our genomes? The oversight
can be partly blamed on current annota-
tion strategies, which are not yet suffi-
ciently fine-tuned to discern small ORFs
among the genomic noise and tend to
relegate most lncRNA sequences to the
non-coding pile. In fact, typical algorithms
for identification of ORFs discard se-
quences less than 100 aa in length. It’s
obviously time for a second look at this
rich source of potential regulators, which
are now being identified with new meth-
odologies (Bazzini et al., 2014). The au-
thors (Anderson et al., 2015) attribute their
success in discovering MLN to sequence
conservation and the presence of an iden-
tifiable functional domain. Perhaps a
multitude of these micropeptides waits
to be discovered, controlling the activity
of ubiquitous enzymes in exquisitely tis-
sue-restricted patterns.
More intriguing questions remain.
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Figure 1. Enhancing Muscle Performance by Restricting MLN
In normal muscle cells (left), MLN (dark red) binds to SERCA (blue) in the membrane of the sarcoplasmic
reticulum (SR) and restricts the import of calcium. In reducedMLN (right), SERCA pump activity is liberated
to keep calcium high in the SR lumen, resulting in higher calcium availability and increased export by
ryanodine receptors (orange) to increase contraction of working muscle cells and improve performance.
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exert more subtle controls on muscle
contraction? In the case of PLN, inhibition
of calcium traffic is mediated by protein
phosphorylation, which may also be a
regulatory feature of MLN action. As in
the actinin-3 polymorphism, which en-
hances elite power and sprint perfor-
mance (Head et al., 2015), do some of
our high-performance athletes harbor
natural mutations in MLN that ensure bet-
ter muscle function? It will be of interest
to determine the role of MLN in muscle
diseases specifically targeting SERCA516 Cell Metabolism 21, April 7, 2015 ª2015function, such as Brody myopathy
(Guglielmi et al., 2013). Being small
and skeletal muscle-specific, MLN repre-
sents a particularly attractive target for
drugs or small molecules to improve mus-
cle contractility in the aged or in debili-
tating degenerative diseases such as
amyotrophic lateral sclerosis or spinal
muscular atrophy. Long-term side effects
that could have been missed in the
initial MLN KO mouse analysis might
emerge to counter-indicate this thera-
peutic approach, but may not deter
professional athletes more focused onElsevier Inc.the most immediate benefits of perfor-
mance-enhancement regimes.
The first eukaryotic micropeptides were
characterized in 2002, translated from
polycistronic plant mRNA (Rohrig et al,
2002). In the last fifteen years, only a hand-
ful of additional micropeptides have been
fully annotated (reviewed in Andrews and
Rothnagel, 2014). Common features
include the lack of an N-terminal signal
sequence, although some micropeptides
have cell-non-autonomous functions,
suggesting potential translocation pro-
perties yet to be described. These find-
ings are humbling: despite extraordinary
technical advances in genomic data gath-
ering and analysis, our understanding of
the genetic circuitry encoded within our
DNA is still remarkably patchy. We are
taking small but important steps.REFERENCES
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